Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07047755 | Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | not yet recruiting | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 2, 2025 | clinicaltrials |
| NCT07043907 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | not yet recruiting | Phase 2 | 115 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 0 | Jul 1, 2025 | clinicaltrials |
| NCT07045805 | Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | not yet recruiting | Phase 2 | 66 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT07044349 | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 2 | 72 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Jun 30, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04901741 | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer(OPTIMUS) | not yet recruiting | Phase 2 | 60 | TME Pharma AGINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07041437 | Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07032532 | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | not yet recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07038460 | A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC(NEO-LISI) | not yet recruiting | Phase 2 | 134 | Wen-zhao ZHONGOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035392 | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 32 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | not yet recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | not yet recruiting | Phase 2 | 22 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jun 22, 2025 | clinicaltrials |
| NCT06057831 | PET/MRI in Rectal Cancer | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 0 | Jun 18, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07021950 | AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 0 | Jun 15, 2025 | clinicaltrials |
| NCT06646445 | Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.(PREMICES) | not yet recruiting | Phase 2 | 60 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | not yet recruiting | Phase 2 | 75 | British Columbia Cancer AgencyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019181 | Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma | not yet recruiting | Phase 2 | 26 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium(WE-FiERCE) | not yet recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07011823 | Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC(KEY-MELT) | not yet recruiting | Phase 2 | 20 | Gangnam Severance HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07014215 | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy | not yet recruiting | Phase 2 | 52 | Anhui Provincial Cancer HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | not yet recruiting | Phase 2 | 46 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT07007728 | Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | not yet recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07008053 | BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 37 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07009145 | QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC | not yet recruiting | Phase 2 | 22 | Qianfoshan HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07003464 | Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT07003815 | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 62 | Tongji HospitalOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT07000305 | A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer(SUPβORT) | not yet recruiting | Phase 2 | 42 | Tao ZhangOTHER | 1 | Jun 2, 2025 | clinicaltrials |
| NCT06848439 | Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer | not yet recruiting | Phase 2 | 26 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06998719 | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC(ACCESS) | not yet recruiting | Phase 2 | 80 | Bi NanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06999252 | Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients | not yet recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06991491 | Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004) | not yet recruiting | Phase 2 | 29 | West China HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06993025 | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT01777919 | Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform(GLIODIS) | not yet recruiting | Phase 2 | 32 | Olympion Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06987123 | TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial | not yet recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT06986057 | Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer | not yet recruiting | Phase 2 | 28 | Shandong Tumor HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06965738 | Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain(BOLT) | not yet recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | May 21, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 2, 2025source: clinicaltrials